The Sunset Date Is on the Headset. Not on the Habit.

Meta is discontinuing support for the Quest 2 and Quest Pro headsets, with the last software update arriving in early next year and the development of HorizonOS being scaled back ahead of the release of Meta VR Glasses in the spring. This news might initially seem hardware-focused, but it carries significant implications for users who rely on their devices for specific therapeutic purposes.

One such application is Amblyotube, a VR software developed by Seven Sports that offers visual coordination and attention exercises to treat amblyopia, or lazy eye.

Amblyotube's innovative approach to treatment is grounded in the science of habit formation. Rather than demanding intense, irregular sessions, the software encourages users to engage in brief daily exercises, lasting between 30 and 40 minutes, over an extended period. This approach aligns with the proven benefits of amblyopia therapy, which emphasizes consistent practice to reinforce the weaker eye's capabilities.

The software runs on Meta Quest headsets and delivers visually engaging content while simultaneously running a separate visual experience for each eye. The dominant eye is treated with a gentle digital blur, while the amblyopic eye undergoes a more intensive process involving AI-powered sharpening, bold red outlines, yellow-green highlights, pulsing flickers, and optional occlusion that effectively isolates each eye's perspective.

At the heart of the experience is a rhythmic, consistent flicker that guides the user's brain to fuse both images, thereby strengthening binocular vision and depth perception.

The engineering behind Amblyotube presents several compelling design choices. Rather than applying a global filter to the dominant eye, the software utilizes per-eye rendering, allowing the content to remain watchable while the therapeutic signal is isolated. The AI Sharpener dynamically detects human figures in the scene and applies the red outline and pulsing flicker, targeting the areas where binocular fusion is most crucial.

The rhythmic flicker, coupled with a contrasting focus cue, provides the amblyopic eye with a steady target and promotes the brain's convergence process.

Setting up the software is straightforward and adaptable to individual needs. Users can select their affected eye, choose a severity level based on their prescribed treatment plan, or run a LogMAR vision check to determine the appropriate intensity. The software supports either virtual reality or augmented reality experiences, and the user can choose their content from a variety of options.

Importantly, Amblyotube does not replace professional medical advice or treatment, but rather serves as a supplementary tool to support users in their visual training journey.

As Meta winds down its headset support, the future of amblyopia therapy may well rest on software like Amblyotube. The headset-dependent constraint of traditional treatments is being overcome by the development of adaptable, on-device tools that can provide consistent, effective training regardless of the hardware in use. The lessons from this story extend beyond Amblyotube and the Quest 2: building software whose value persists beyond the hardware cycle is a key consideration for developers in the evolving landscape of XR technology.